1 Kessler RC, "Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States" 21 : 169-184, 2012
2 Merikangas KR, "The spectrum of social phobia in the Zurich cohort study of young adults" 51 : 81-91, 2002
3 Kessler RC, "The impairments caused by social phobia in the general population: implications for intervention" 19-27, 2003
4 Stein MB, "Social phobia symptoms, subtypes, and severity: findings from a community survey" 57 : 1046-1052, 2000
5 Burstein M, "Social phobia and subtypes in the national comorbidity surveyadolescent supplement: prevalence, correlates, and comorbidity" 50 : 870-880, 2011
6 Culpepper L, "Social anxiety disorder in the primary care setting" 67 (67): 31-37, 2006
7 Keller MB, "Social anxiety disorder clinical course and outcome: review of Harvard/Brown Anxiety Research Project (HARP) findings" 67 (67): 14-19, 2006
8 Davidson JR, "Pharmacotherapy of social anxiety disorder: what does the evidence tell us?" 67 (67): 20-26, 2006
9 Pae CU, "Paroxetine: current status in psychiatry" 7 : 107-120, 2007
10 Kessler RC, "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication" 62 : 593-602, 2005
1 Kessler RC, "Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States" 21 : 169-184, 2012
2 Merikangas KR, "The spectrum of social phobia in the Zurich cohort study of young adults" 51 : 81-91, 2002
3 Kessler RC, "The impairments caused by social phobia in the general population: implications for intervention" 19-27, 2003
4 Stein MB, "Social phobia symptoms, subtypes, and severity: findings from a community survey" 57 : 1046-1052, 2000
5 Burstein M, "Social phobia and subtypes in the national comorbidity surveyadolescent supplement: prevalence, correlates, and comorbidity" 50 : 870-880, 2011
6 Culpepper L, "Social anxiety disorder in the primary care setting" 67 (67): 31-37, 2006
7 Keller MB, "Social anxiety disorder clinical course and outcome: review of Harvard/Brown Anxiety Research Project (HARP) findings" 67 (67): 14-19, 2006
8 Davidson JR, "Pharmacotherapy of social anxiety disorder: what does the evidence tell us?" 67 (67): 20-26, 2006
9 Pae CU, "Paroxetine: current status in psychiatry" 7 : 107-120, 2007
10 Kessler RC, "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication" 62 : 593-602, 2005
11 Bruce SE, "Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study" 162 : 1179-1187, 2005
12 Association AP, "Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)" American Psychiatric Press 1994
13 Chartier MJ, "Considering comorbidity in social phobia" 38 : 728-734, 2003
14 Merikangas KR, "Comorbidity and social phobia: evidence from clinical, epidemiologic, and genetic studies" 244 : 297-303, 1995
15 Stein MB, "An epidemiologic perspective on social anxiety disorder" 67 (67): 3-8, 2006